iZumi Bio, a company specializing in stem-cell research used to create a range of treatments, has landed $20 million in first-round funding and a partnership with Kyoto University in Japan to conduct parallel studies and collaborate on the results.
One of the company’s primary investors is Kleiner Perkins Caufield & Byers, a... (Read more)
Reprinted with permission from VentureBeat. Story copyright 2009 VentureBeat Inc. All rights reserved.
Post new comment